During experimental autoimmune encephalomyelitis, ex vivo experiments demonstrated that treatment with decitabine reduced the T cell infiltrate in the central nervous system and the activation of resident macrophages, with reduction in CD45 and MHC class II expression. Here, PTPRC is linked to experimental autoimmune encephalomyelitis.